$STVN: Are Oral GLP-1s Really a Death Blow? | Aurelian Research's Leo Trudel

Why It Matters

Stevanato’s shifting revenue mix and free‑cash‑flow upside make it a potentially undervalued play in the growing biologics market, despite short‑term fears over oral GLP‑1 competition.

Key Takeaways

• Stevanato supplies glass vials to 23 of top 24 pharma.
• COVID‑era demand surged, then flattened during destocking, now recovering.
• Oral GLP‑1 drugs threaten injectable demand, risking overcapacity.
• Margin expansion driven by high‑value pre‑sterilized solutions shifting mix.
• Free‑cash‑flow positivity and ~10% IRR suggest undervalued opportunity.

Summary

The podcast examines Stevanato Group (STVN), an Italian glass‑vial and containment‑system maker serving the world’s largest pharma firms. Its business surged during the COVID‑19 vaccine boom, later flattened as customers destocked, and is now rebounding as demand for biologic injectables resumes.

Leo Trudel highlights three core dynamics: a massive capex cycle built for GLP‑1 injectable growth, a revenue mix split between high‑margin pre‑sterilized solutions (growing 15‑18%) and low‑margin legacy lines (growing ~2%), and a valuation gap where the stock trades at 11‑13× EBITDA despite a 40× cash‑flow multiple on a free‑cash‑flow‑positive basis.

Trudel notes, “The market overreacted to oral GLP‑1 announcements; injectable volumes will still grow, and margin expansion comes without cost cuts.” He also points to a projected mid‑teens growth for GLP‑1 injectables in FY25 and an EBITDA margin trajectory toward 30‑32% over five years.

For investors, the combination of overcapacity concerns, a clear margin‑expansion pathway, and a free‑cash‑flow‑driven IRR of roughly 8‑12% creates a risk‑adjusted alpha opportunity, especially if the market continues to undervalue the long‑term biologics demand tail.

Original Description

Stevanato (STVN) makes the glass vials and pre-filled syringes that GLP-1 drugs ship in. The stock has sold off on fears that oral GLP-1s replace injectables, but Aurelian Research's Leo Trudel argues that's a misread: biologics demand keeps growing, the mix is shifting toward higher-margin "high-value solutions," and switching costs in regulated drug delivery are real. We dig into the bull case, the oral-vs-injectable debate, capacity and oversupply risk, capital allocation, regulatory lock-in, and what would change Leo's view.

[00:00:00] Podcast intro and guest welcome

[00:03:08] Stevanato's business model: vials, syringes, high-value solutions

[00:03:51] COVID boom and the destocking cycle

[00:06:39] Why the stock sold off and what it implies

[00:07:34] Market expectations vs. reality

[00:11:55] Margin expansion from mix shift

[00:14:40] Oral vs. injectable GLP-1s: the real debate

[00:17:30] Why oral and injectable aren't interchangeable

[00:19:44] Capacity additions and oversupply risk

[00:21:00] Biologics demand beyond GLP-1

[00:23:04] Management trust and capital allocation

[00:26:52] Regulatory lock-in: the real moat

[00:29:42] What could break the bull case

[00:30:53] Future capex and where it goes

[00:32:41] Industry structure and M&A outlook

[00:34:37] AI tools in investment research

[00:38:09] Closing thoughts and Leo's stance

Links:

Yet Another Value Blog - https://www.yetanothervalueblog.com

See our legal disclaimer here: https://www.yetanothervalueblog.com/p/legal-and-disclaimer

Production and editing by The Podcast Consultant - https://thepodcastconsultant.com/